Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Merck to Showcase Oncology Pipeline at Investor Day Amid Concerns About Dependence on Keytruda

With two new approvals for the vaunted checkpoint inhibitor Keytruda and a rapidly expanding oncology pipeline following M&A deals, Merck & Co. plans to share outlines for the future of the company’s cancer treatment at the first investor day held in five years.

Read More »

Sanofi plans 466 job cuts as part of R&D reshuffle

Sanofi said a reorganization of the company’s research and development operation in Germany and France would result in 466 job cuts in the two countries.

Read More »

Gilead and Nurix Establish Strategic Collaboration

Gilead Sciences Inc. and Nurix Therapeutics Inc. announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.

Read More »

FDA Action Alert: Merck, Agios and AMAG Pharma

June 2019 is a busy month for approval applications for the U.S. Food and Drug Administration as the regulatory agency has a slate of PDUFA dates.

Read More »

Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.

Read More »

Pfizer bolsters cancer portfolio with Array deal

Pfizer Inc. struck a deal with an enterprise value of about $11.4 billion to buy Array BioPharma Inc. to expand the company’s portfolio of potentially lucrative cancer drugs.

Read More »

U.S. drugmakers file lawsuit over TV ad drug pricing

U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.

Read More »

AbCellera and Gilead Forge Infectious Disease Pact

Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.

Read More »

BlackThorn Raises $76 Million to Advance Drugs for Neurobehavioral Disorders

San Francisco-based BlackThorn Therapeutics announced closing on a $76 million Series B financing round.

Read More »

FDA blockchain collaboration: IBM, Walmart, Merck

IBM, Merck and Walmart were chosen for a U.S. FDA pilot program that will explore using blockchain technology to improve the security of prescription drug supply and distribution.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom